Arrowhead Research ($ARWR) reported a net loss of $58.7 million in fiscal year 2014, up from $31.7 million in FY 2013. R&D expenses nearly tripled in FY 2014 to $23.1 million, as the company races to develop a commercial therapy before investors lose patience. Its stock fell about 50 cents on the Nov. 25 news and now stands at a little under $6. Release